Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown

Abstract Objectives To identify a safe pathway for management and treatment of patients with X-linked hypophosphatemic rickets (XLH) during Covid-19 pandemic lockdown. Methods Twenty-six XLH (age 3.1–25.7 years) were enrolled in Pediatric Endocrine Unit; nine them receiving human monoclonal anti-fibroblast growth factor 23 antibody (burosumab) 17 (pediatric patients, age 9.5–17.9 years, n=7; young-adult 20.1–25.7 n=10) received conventional inorganic oral phosphate salts active vitamin D metabolites. A free was addressed burosumab hospital. followed by phone calls, e-mails, or telemedicine. Results All continued the scheduled follow-up treatment; none infected Covid-19. Seven out (41%) showed some complication related to disease itself its treatment: periapical abscess gingival fistula diagnosed five (three children two young-adults) treated antibiotics complete resolution; one child abdominal pain due administration high doses solved reducing dosage, had severe legs deambulation after orthopedic surgery common analgesics. Conclusions effective manage burosumab. E-health technologies useful methods follow